

# Zhenghe Wang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7921213/publications.pdf>

Version: 2024-02-01

50  
papers

5,701  
citations

257357

24  
h-index

214721

47  
g-index

53  
all docs

53  
docs citations

53  
times ranked

9853  
citing authors

#	ARTICLE	IF	CITATIONS
1	High Frequency of Mutations of the PIK3CA Gene in Human Cancers. <i>Science</i> , 2004, 304, 554-554.	6.0	3,048
2	Mutational Analysis of the Tyrosine Phosphatome in Colorectal Cancers. <i>Science</i> , 2004, 304, 1164-1166.	6.0	498
3	DNMT1 Stability Is Regulated by Proteins Coordinating Deubiquitination and Acetylation-Driven Ubiquitination. <i>Science Signaling</i> , 2010, 3, ra80.	1.6	278
4	Inhibition of the prostaglandin-degrading enzyme 15-PGDH potentiates tissue regeneration. <i>Science</i> , 2015, 348, aaa2340.	6.0	220
5	Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer. <i>Nature Communications</i> , 2016, 7, 11971.	5.8	203
6	DNMT1-associated long non-coding RNAs regulate global gene expression and DNA methylation in colon cancer. <i>Human Molecular Genetics</i> , 2015, 24, 6240-6253.	1.4	167
7	Targeted inactivation of CTNNB1 reveals unexpected effects of $\beta$ -catenin mutation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 8265-8270.	3.3	120
8	Inhibition of intracellular lipolysis promotes human cancer cell adaptation to hypoxia. <i>ELife</i> , 2017, 6, .	2.8	104
9	Epitope tagging of endogenous proteins for genome-wide ChIP-chip studies. <i>Nature Methods</i> , 2008, 5, 163-165.	9.0	92
10	Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 1114-1119.	3.3	86
11	Gain of Interaction with IRS1 by p110 $\beta$ -Helical Domain Mutants Is Crucial for Their Oncogenic Functions. <i>Cancer Cell</i> , 2013, 23, 583-593.	7.7	85
12	Identification and functional characterization of paxillin as a target of protein tyrosine phosphatase receptor T. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 2592-2597.	3.3	69
13	5-Fluorouracil Enhances the Antitumor Activity of the Glutaminase Inhibitor CB-839 against <i>PIK3CA</i> -Mutant Colorectal Cancers. <i>Cancer Research</i> , 2020, 80, 4815-4827.	0.4	49
14	Phosphorylation of beta-catenin at S33, S37, or T41 can occur in the absence of phosphorylation at T45 in colon cancer cells. <i>Cancer Research</i> , 2003, 63, 5234-5.	0.4	47
15	Tumor-Derived Extracellular Mutations of PTPRT/PTP $\beta$ Are Defective in Cell Adhesion. <i>Molecular Cancer Research</i> , 2008, 6, 1106-1113.	1.5	44
16	A Protein Interaction between $\beta$ -Catenin and Dnmt1 Regulates Wnt Signaling and DNA Methylation in Colorectal Cancer Cells. <i>Molecular Cancer Research</i> , 2015, 13, 969-981.	1.5	44
17	Hypoxia-mediated regulation of Cdc25A phosphatase by p21 and miR-21. <i>Cell Cycle</i> , 2009, 8, 3157-3164.	1.3	39
18	Colorectal cancers utilize glutamine as an anaplerotic substrate of the TCA cycle in vivo. <i>Scientific Reports</i> , 2019, 9, 19180.	1.6	37

#	ARTICLE	IF	CITATIONS
19	Novel thiourea-based sirtuin inhibitory warheads. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 3319-3324.	1.0	36
20	Cancer driver candidate genes AVL9, DENND5A and NUPL1 contribute to MDCK cystogenesis. <i>Oncoscience</i> , 2014, 1, 854-865.	0.9	34
21	Tumour suppressor function of protein tyrosine phosphatase receptor-T. <i>Bioscience Reports</i> , 2011, 31, 303-307.	1.1	31
22	From spindle checkpoint to cancer. <i>Nature Genetics</i> , 2004, 36, 1144-1145.	9.4	28
23	Regulation of paxillin-p130-PI3K-AKT signaling axis by Src and PTPRT impacts colon tumorigenesis. <i>Oncotarget</i> , 2017, 8, 48782-48793.	0.8	28
24	PTPRT Regulates High-Fat Diet-Induced Obesity and Insulin Resistance. <i>PLoS ONE</i> , 2014, 9, e100783.	1.1	26
25	Cancer-Derived Mutations in the Fibronectin III Repeats of PTPRT/PTP $\beta$ Inhibit Cell-Cell Aggregation. <i>Cell Communication and Adhesion</i> , 2010, 16, 146-153.	1.0	25
26	Characterization of the Adhesive Properties of the Type IIb Subfamily Receptor Protein Tyrosine Phosphatases. <i>Cell Communication and Adhesion</i> , 2010, 17, 34-47.	1.0	24
27	A mechanism-based potent sirtuin inhibitor containing N $\mu$ -thiocarbamoyl-lysine (TuAck). <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 4753-4757.	1.0	22
28	Discovery of potent, proteolytically stable, and cell permeable human sirtuin peptidomimetic inhibitors containing N $\mu$ -thioacetyl-lysine. <i>MedChemComm</i> , 2010, 1, 233.	3.5	21
29	Identifying Novel Protein Complexes in Cancer Cells Using Epitope-Tagging of Endogenous Human Genes and Affinity-Purification Mass Spectrometry. <i>Journal of Proteome Research</i> , 2012, 11, 5630-5641.	1.8	20
30	Potent sirtuin inhibition bestowed by l-2-amino-7-carboxamidoheptanoic acid (l-ACAH), a N $\mu$ -acetyl-lysine analog. <i>MedChemComm</i> , 2011, 2, 291.	3.5	19
31	How do oncoprotein mutations rewire protein-protein interaction networks?. <i>Expert Review of Proteomics</i> , 2015, 12, 449-455.	1.3	18
32	Noninvasive assessment and therapeutic monitoring of drug-resistant colorectal cancer by MR molecular imaging of extradomain-B fibronectin. <i>Theranostics</i> , 2020, 10, 11127-11143.	4.6	14
33	Targeting glutamine metabolism in PIK3CA mutant colorectal cancers. <i>Genes and Diseases</i> , 2016, 3, 241-243.	1.5	13
34	Nuclear translocation of p85 $\beta$ promotes tumorigenesis of PIK3CA helical domain mutant cancer. <i>Nature Communications</i> , 2022, 13, 1974.	5.8	13
35	Epitope Tagging of Endogenous Proteins for Genome-Wide Chromatin Immunoprecipitation Analysis. <i>Methods in Molecular Biology</i> , 2009, 567, 87-98.	0.4	12
36	STAT3 as a Chemoprevention Target in Carcinogen-Induced Head and Neck Squamous Cell Carcinoma. <i>Cancer Prevention Research</i> , 2016, 9, 657-663.	0.7	12

#	ARTICLE	IF	CITATIONS
37	Targeting the Protein-Protein Interaction between IRS1 and Mutant p110 $\beta$ for Cancer Therapy. Toxicologic Pathology, 2014, 42, 140-147.	0.9	11
38	Phase I clinical trial of the glutaminase inhibitor CB-839 plus capecitabine in patients with advanced solid tumors.. Journal of Clinical Oncology, 2018, 36, 2562-2562.	0.8	9
39	Replication-Related Activities Establish Cohesion Between Sister Chromatids. Cell Biochemistry and Biophysics, 2001, 35, 289-301.	0.9	8
40	CtIP is required for DNA damage-dependent induction of $\gamma$ -H2AX. Cell Cycle, 2014, 13, 90-95.	1.3	8
41	Adverse Clinical Outcome Associated With Mutations That Typify African American Colorectal Cancers. Journal of the National Cancer Institute, 2016, 108, djw164.	3.0	7
42	Novel all-hydrocarbon stapled p110 $\beta$ [E545K] peptides as blockers of the oncogenic p110 $\beta$ [E545K]-IRS1 interaction. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 5446-5449.	1.0	7
43	Multiproteomic and Transcriptomic Analysis of Oncogenic $\beta$ -Catenin Molecular Networks. Journal of Proteome Research, 2018, 17, 2216-2225.	1.8	6
44	Quantitative Analysis of Alternative Pre-mRNA Splicing in Mouse Brain Sections Using RNA <i>In Situ</i> Hybridization Assay. Journal of Visualized Experiments, 2018, , .	0.2	6
45	Mutations in TP53, ZNF750, and RB1 typify ocular sebaceous carcinoma. Journal of Genetics and Genomics, 2019, 46, 315-318.	1.7	5
46	Deep proteomic analysis of Dnmt1 mutant/hypomorphic colorectal cancer cells reveals dysregulation of epithelial-mesenchymal transition and subcellular re-localization of Beta-Catenin. Epigenetics, 2020, 15, 107-121.	1.3	4
47	A facile and sensitive method of quantifying glutaminase binding to its inhibitor CB-839 in tissues. Journal of Genetics and Genomics, 2020, 47, 389-395.	1.7	4
48	Research highlights from AACR members. Genes and Diseases, 2018, 5, 301.	1.5	0
49	Abstract B03: Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancers. , 2016, , .		0
50	Targeting glutamine metabolism in PIK3CA mutant colorectal cancers. Molecular and Cellular Oncology, 0, , 00-00.	0.3	0